System and method for aligning an optic with an axis of an eye

• US 20060184243A1
• Filed: 10/24/2005
• Published: 08/17/2006
• Est. Priority Date: 10/22/2004
• Status: Abandoned Application

• Current Assignee: Acufocus, Inc.
• Original Assignee: Acufocus, Inc.
• Inventors: Yilmaz, Omer
• Application Number:
  US11/257,505
• Publication Number:
  US 20060184243A1
• Time in Patent Office: Days
• US Class Current: 623/4.100
• CPC Class Codes: A61F 2/148 Implantation instruments specially adapted therefor
• CPC Class Codes: A61F 2/15 Implant having one or more holes, e.g. for nutrient transport, for facilitating handling
• CPC Class Codes: A61F 2250/0097 Visible markings, e.g. indicia
• CPC Class Codes: A61F 9/0008 Introducing ophthalmic products into the ocular cavity or retaining products therein putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00
• CPC Class Codes: A61F 9/00834 Inlays; Onlays; Intraocular lenses [IOL]
• CPC Class Codes: A61F 9/04 Eye-masks ; Devices to be worn on the face, not intended for looking through; Eye-pads for sunbathing eye-bandages A61F13/12; protective face-masks A41D13/11; protectors for shampooing A45D

Abstract

A method increases the depth of focus of an eye having a line of sight. A pharmacologic agent is applied to the eye to cause a reduction in the size of the pupil of the eye. The pupil is aligned with a visible feature of a mask comprising a pin-hole aperture. The pin-hole aperture is centered on a mask axis. The alignment causes the mask axis to be substantially aligned with the line of sight of the eye. The mask is applied to the eye of the patient while maintaining the alignment of the visible feature of the mask and the pupil.

Claims

1. A kit for aligning an ocular implant with a visible ocular feature of an eye of a patient, comprising:

a pharmacologic agent configured to be applied to the eye and to increase the correlation between the location of a visible ocular feature and the line of sight of the eye; and

a mask comprising a small aperture having a mask axis and a visible mask feature, the visible mask feature being configured to be aligned with the visible ocular feature to substantially align the mask axis with the line of sight.

2. The kit of claim 1, wherein the eye comprises a pupil and the pharmacologic agent is configured to reduce the size of the pupil when applied to the eye.

3. The kit of claim 1, wherein the pharmacologic agent comprises pilocarpine.

4. The kit of claim 1, wherein the pharmacologic agent is selected from the group consisting of:

carbachol, demecarium, isoflurophate, physostigmine, aceclidine, and echothiophate.

5. The kit of claim 1, wherein the eye comprises a pupil and the pharmacologic agent is configured to increase the size of the pupil.

6. The kit of any of claim 1, wherein the visible feature of the mask includes at least one of an inner periphery and an outer periphery of the mask.

7. The kit of any of claim 1, wherein the visible feature of the mask comprises at least one window portion located between the inner periphery and the outer periphery of the mask through which the pupil may be viewed.

8. A mask configured to be implanted in a cornea of a patient to increase the depth of focus of the patient, the mask comprising:

an anterior surface configured to reside adjacent a first corneal layer;

a posterior surface configured to reside adjacent a second corneal layer;

an aperture configured to transmit along an optic axis substantially all incident light;

a substantially opaque portion surrounding at least a portion of the aperture; and

at least one window portion formed in the opaque portion through which a visible ocular feature of an eye can be observed to facilitate alignment of the mask with the line of sight of the patient'"'"'s eye.

9. The mask of claim 8, wherein the at least one window portion comprises clear graduations.

10. The mask of claim 8, wherein the eye comprises a pupil and the at least one window portion comprises partially opaque regions through which the pupil can be viewed.

11. The mask of claim 8, wherein the at least one window portion comprises partially opaque regions through which the visible ocular feature can be viewed.

12. The mask of any of claim 8, wherein the mask comprises at least two window portions located between an inner periphery and an outer periphery of the mask through which the visible ocular feature can be viewed.

13. A method of increasing the depth of focus of an eye of a patient, the eye having a cornea and a line of sight, the method comprising:

applying a pharmacologic agent to the eye to cause a reduction in the size of the pupil of the eye;

aligning with the pupil a visible feature of a mask comprising a pin-hole aperture centered on a mask axis, the alignment of the visible feature with the pupil causing the mask axis to be substantially aligned with the line of sight of the eye; and

applying the mask to the eye of the patient while maintaining the alignment of

the visible feature of the mask and the pupil.

14. The method of claim 13, wherein the pharmacologic agent is selected from the group consisting of:

pilocarpine, carbachol, demecarium, isoflurophate, physostigmine, aceclidine, and echothiophate.

15. The method of claim 13, wherein the visible feature of the mask includes at least one of an inner periphery and an outer periphery of the mask.

16. The method of claim 13, wherein the visible feature of the mask comprises at least two window portions located between the inner periphery and the outer periphery of the mask through which the pupil may be viewed.

17. The method of claim 13, wherein the mask further comprises a plurality of holes extending at least partially between the anterior surface and the posterior surface, the plurality of holes being configured to substantially eliminate diffraction patterns visible to the patient.

18. The method of claim 17, wherein the plurality of holes is configured to substantially prevent nutrient depletion in adjacent corneal tissue.

19. The method of claim 17, wherein a non-uniform spacing is provided between a substantial number of the plurality of holes.

20. The method of claim 17, wherein a substantial number of the holes are configured to prevent incident light from passing therethrough.

21. The method of claim 13, wherein applying the mask further comprises:

hinging open a corneal flap, the corneal flap located at a depth selected from the group consisting of;

about the outermost 20% of the thickness of the cornea, about the outermost 10% of the thickness of the cornea, about the outermost 5% of the thickness of the cornea, less than about the outermost 5% of the thickness of the cornea, in the range of about the outermost 5% to about the outermost 10% of the thickness of the cornea, in the range of about the outermost 5% to about the outermost 20% of the thickness of the cornea;

placing the mask on the cornea while maintaining the alignment of the visible feature of the mask and the pupil; and

placing the hinged corneal flap over the mask.

22. The method of claim 21, further comprising placing a contact lens over a portion of the cornea until an epithelial sheet adheres to the mask and the stroma.

23. The method of claim 13, wherein applying the mask further comprises:

removing an epithelial sheet of the cornea;

creating a depression in the Bowman'"'"'s membrane at a position corresponding to the pupil, the depression being sufficiently deep to expose the stroma and being configured to receive the mask;

placing the mask on the cornea while maintaining the alignment of the visible feature of the mask and the pupil; and

placing the removed epithelial sheet over the mask.

24. The method of claim 23, further comprising placing a contact lens over a portion of the cornea until the epithelial sheet has adhered to the mask.

25. The method of claim 13, wherein applying the mask further comprises:

hinging open a portion of the Bowman'"'"'s membrane;

creating a depression in the top layer of the stroma at a position corresponding to the pupil, the depression being configured to receive the mask;

placing the mask in the depression; and

placing the hinged Bowman'"'"'s membrane over the mask.

26. The method of claim 25, further comprising placing a contact lens over a portion of the cornea until an epithelial sheet has grown over the hinged Bowman'"'"'s membrane.

27. The method of claim 13, wherein applying the mask further comprises:

creating a channel in the top layer of the stroma, the channel being in a plane parallel to the anterior surface of the cornea, the channel being formed in a position corresponding to the pupil; and

placing the mask in the channel while maintaining the alignment of the visible feature of the mask and the pupil.

28. The method of claim 27, wherein placing the mask further comprises threading the mask into the channel.

29. The method of claim 27, wherein placing the mask further comprises injecting the mask into the channel.

30. The method of claim 13, wherein applying the mask further comprises:

penetrating the top layer of the stroma with an injecting device; and

injecting the mask into the top layer of the stroma with the injecting device at a position corresponding to the pupil.

31. The method of claim 30, wherein the injecting device comprises a ring of needles.

32. The method of claim 13, wherein applying the mask further comprises:

creating a pocket in the stroma at a position corresponding to the pupil, the pocket being configured to receive the mask; and

placing the mask in the pocket such that the visible feature of the mask is at a selected position relative to the pupil.

33. A method for increasing the depth of focus of a eye of a patient, the eye comprising a visible ocular feature and a line of sight, the method comprising:

treating the eye to increase the correlation between the location of the visible ocular feature and the line of sight; and

applying to the eye a mask comprising a pin-hole aperture having a mask axis such that a visible feature of the mask is aligned with the visible ocular feature and the mask axis is substantially aligned with the line of sight.

34. The method of claim 33, wherein the visible ocular feature is a pupil of the eye.

35. The method of claim 34, wherein treating the eye comprises applying a pharmacologic agent to reduce the size of the pupil.

36. The method of claim 35, wherein the pharmacologic agent is selected from the group consisting of:

pilocarpine, carbachol, demecarium, isoflurophate, physostigmine, aceclidine, and echothiophate.

37. The method of claim 34, wherein treating the eye comprises applying a pharmacologic agent to increase the size of the pupil.

38. The method of claim 34, wherein treating the eye comprises directing a light into the eye to cause the pupil size to be reduced.

39. The method of claim 33, wherein the visible feature of the mask includes at least one of an inner periphery and an outer periphery of the mask.

40. A method for correcting vision, comprising:

performing a LASIK procedure;

treating the eye to alter a visible ocular feature;

applying the mask to the eye such that a visible feature of a mask is aligned with the visible ocular feature, the mask comprising a pin-hole aperture having a mask axis.

41. The method of claim 40, wherein treating the eye comprises applying a pharmacologic agent to reduce the size of the pupil.

42. The method of claim 41, wherein the pharmacologic agent is selected from the group consisting of:

pilocarpine, carbachol, demecarium, isoflurophate, physostigmine, aceclidine, and echothiophate.